This article examines viral and non-viral vectors in gene therapy, highlighting their mechanisms, advantages, and limitations ...

Organoids were cultured from healthy donor iPSC sources and differentiated using the human iPSC-derived Cerebral Organoid ...

Amid a broader push to beef up cell and gene therapy manufacturing capacity in Europe, Novartis has opened the doors to a €40 ...

The cuts at two Massachusetts plants follow further site closures and layoffs across the company over the past few years.

Gene therapy is usually reserved for severe and ... Here we show that an orally administered adeno-associated viral vector leads to persistent expression of a ß-galactosidase transgene in both ...

Explore a comprehensive guide to standardizing large scale production and clarification of lentiviral vectors.

Despite recent evidence of its financial turnaround, Thermo Fisher’s layoff spree will continue into 2025. | Despite recent ...

Viralgen and Axovia Therapeutics are set to form a partnership to progress the development and manufacturing of an adeno-associated virus vector serotype 9 (AAV9)-based gene therapy for retinal ...

One of the original pioneers in cell and gene therapy, OXB has more than 25 years of experience ... world's most innovative pharmaceutical and biotechnology companies, providing viral vector ...

The majority are in the very early preclinical stage of development, but applications for regulatory approval have been ...

CSL Behring's gene therapy Hemgenix four years post-infusion data continue to show sustained efficacy and safety in adults with haemophilia B: King of Prussia, Pennsylvania Monday ...

BioViva’s journey in gene therapy began with its use of an adeno-associated virus (AAV) vector. The company’s lead gene therapy, BV-702, is AAV-based and is in preclinical development for ...